Revvity reported strong Q2 results, beating on EPS, driven partly by one-time tariff refunds, and raised its full-year guidance citing an improving pharma/biotech environment and accelerating AI-driven demand for its high-content screening and software offerings. The company highlighted a strong order backlog and continued momentum in diagnostics. Q2 revenue of $711M (+3% organic), EPS of $1.41 beat guidance; ~half of EPS beat driven by one-time tariff refunds.
Revvity reported strong Q2 results, beating on EPS, driven partly by one-time tariff refunds, and raised its full-year guidance citing an improving pharma/biotech environment and accelerating AI-driven demand for its high-content screening and software offerings. The company highlighted a strong order backlog and continued momentum in diagnostics. Q2 revenue of $711M (+3% organic), EPS of $1.41 beat guidance; ~half of EPS beat driven by one-time tariff refunds.
Executives express strong optimism about improving end markets, accelerated AI-driven demand, and raised guidance, with Prahlad Singh noting the company is 'beginning to be realized and shine through.'
Management indicates accelerating demand from AI-driven drug discovery, with customers building AI platforms and seeking instruments, reagents, and software for validation and data generation. They are monetizing through new products like Signals AI, the Anthropic MCP…
Full-year organic growth guidance raised to 4-5% (from 3-4%); EPS guidance raised by $0.10 to $5.30-$5.40.
Guidance · revenue to $2.845B
Management indicates accelerating demand from AI-driven drug discovery, with customers building AI platforms and seeking instruments, reagents, and software for validation and data generation. They are monetizing through new products like Signals AI, the Anthropic MCP connector, and high-content screening instruments, positioning themselves as a leader in 'lab-in-the-loop' workflows.
Strongest instrument backlog in 3-4 years entering Q3. Executives express strong optimism about improving end markets, accelerated AI-driven demand, and raised guidance, with Prahlad Singh noting the company is 'beginning to be realized and shine through.'
Management is investing in capacity expansion for high-content screening instruments and reagents to meet accelerating demand, funded partly by tariff refunds. They are also reinvesting in strategic initiatives, supply chain, and people to capitalize on the end-market recovery.
Executives express strong optimism about improving end markets, accelerated AI-driven demand, and raised guidance, with Prahlad Singh noting the company is 'beginning to be realized and shine through.'
“the strongest position that we have seen in terms of backlog we've had in the past three to four years”
“we are also now seeing orders coming directly tied to this AI data generation during the first quarter, which is now becoming a clear trend”
“it positions us even better as we move into the third quarter and back half of the year. It is important to note that this build out by our customers of additional capacity will also result in future improvements in demand for our related…”
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| EPS | FY2026 | $5.30–$5.40 | $5.35 | RAISED |
| Op margin | FY2026 | 28.7% | 28.7% | RAISED |
| Revenue | FY2026 | $2.83B–$2.86B | $2.845B | RAISED |
Revvity is partnering with Anthropic to integrate its LLM into the Signals platform, expanding the functionality of its software and creating stickiness for its customers; this validates Anthropic's push into scientific verticals.
“our newly introduced Anthropic MCP connector now allow scientists to close that loop in ways that were simply not possible before”
… of the experimental cycle itself, continuously learning from results, suggesting next steps, and compressing the time between hypotheses and insight, but importantly generating more unique data than ever possible in the past, is increasingly being referred to by customers as a lab in the loop workflow. Revit's instruments and reagents generate the data. SignalsOne manages and structures it, and our recently released SignalsAI capabilities and our newly introduced Anthropic MCP connector now allow scientists to close that loop in ways that were simply not possible before. These examples highlight how Revity helps power scientific intelligence as we support customers throughout this new discovery process, reinforcing why we are one of the best positioned companies in the entire industry to benefit from the AI-driven transformation of preclinical R&D that is only just beginning to take place. Against this backdrop, our signal software business remains a critical part of how we enable customers to manage and apply scientific data across their workflows. In the second quarter, signals performed in line with our expectations against a very difficult year ago comparison with organic …